Roche has signed a definitive merger agreement for the acquisition of US-based PathAI in a deal valued at up to $1.05bn.
PathAI specialises in digital pathology and AI-powered diagnostics, serving pathology laboratories and the biopharma industry.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Under the deal, Roche will pay $750m in upfront and make additional milestone payments of up to $300m.
Completion of the acquisition is subject to customary closing conditions, including antitrust and regulatory approvals.
The move follows a partnership between Roche and PathAI initiated in 2021 and expanded in 2024 to encompass the development of AI-enabled companion diagnostic algorithms.
PathAI will join Roche’s diagnostics division upon completion, which is expected in the second half of the year.
The acquisition aims to reinforce Roche’s position in digital pathology by enabling the automation of manual workflows into AI-supported processes and insights.
Digital pathology facilitates the conversion of physical tissue slides into high-resolution digital images, allowing pathologists to use AI tools that streamline diagnostic workflows and enable quicker turnaround for patient results.
Roche Diagnostics CEO Matt Sause said: “Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better-tailored treatment regimens.
“Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”
PathAI CEO and co-founder Andy Beck said: “Joining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed.”
PathAI’s AISight IMS software provides a user-friendly interface that integrates advanced analytical and workflow capabilities in digital pathology labs.
Roche intends to scale this solution globally in response to the growing digital pathology market.
The acquisition also enhances Roche’s position in precision medicine by boosting its biopharma services with PathAI’s expertise in AI-driven clinical trial support and translational research.
The combination is expected to accelerate biomarker and diagnostic tool discovery for biopharma partners.
